Snowball logo
logo
CPHI

China Pharma Holdings Inc

CPHI โ€ข NYSE MKT
$0.6348-$0.0238ย  (3.61%)
Estimate
EPS
-0.42
Beta
1.052
Growth
Revenue, YoY
-7.55%
Net income, YoY
-175.97%
FCF, YoY
-111.68%
About the company
Ticker
CPHI
ISIN
US16941T1043
Country
China
Sector (GICS)
Healthcare
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Frequently asked questions

What sector does China Pharma Holdings Inc (CPHI) operate in?

China Pharma Holdings Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is China Pharma Holdings Inc (CPHI) current stock price?

As of the latest data, China Pharma Holdings Inc stock price is $0.63, with a previous close of $0.66. China Pharma Holdings Inc lost -$0.02 in the last trading session, representing a -3.61% loss.

What is China Pharma Holdings Inc (CPHI) current market capitalization?

China Pharma Holdings Inc market cap is approximately 27.31 million.

What is China Pharma Holdings Inc (CPHI) Earnings Per Share (EPS)?

The trailing EPS is -$0.42.

What is China Pharma Holdings Inc (CPHI) EBITDA?

China Pharma Holdings Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -329.91 thousand.

Does China Pharma Holdings Inc (CPHI) pay dividends?

No. China Pharma Holdings Inc does not pay a dividend.

When is China Pharma Holdings Inc (CPHI) next earnings report?

China Pharma Holdings Inc is expected to release its next earnings report on September 30, 2026.

What is China Pharma Holdings Inc (CPHI) beta (volatility) score?

China Pharma Holdings Inc has a beta of 1.052, meaning its volatility is roughly in line with the market.